Related references
Note: Only part of the references are listed.Effect of Darapladib Treatment on Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A2 Activity: A Randomized, Controlled Trial
Joel L. Johnson et al.
PLOS ONE (2014)
Changes in Lipoprotein-Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long-term Intervention with Pravastatin in Ischemic Disease Study
Harvey D. White et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial
Paul M. Ridker et al.
CLINICAL CHEMISTRY (2012)
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
Ph Gabriel Steg et al.
EUROPEAN HEART JOURNAL (2012)
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease
Harvey White et al.
AMERICAN HEART JOURNAL (2010)
Concept of Vulnerable/Unstable Plaque
Aloke V. Finn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
Deepak L. Bhatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality
S. Parish et al.
JOURNAL OF INTERNAL MEDICINE (2010)
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
LANCET (2010)
Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque
Patrick W. Serruys et al.
CIRCULATION (2008)
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
Robert L. Wilensky et al.
NATURE MEDICINE (2008)
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses
Yi Shi et al.
ATHEROSCLEROSIS (2007)
Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis
Frank D. Kolodgie et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin or atorVastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial
M O'Donoghue et al.
CIRCULATION (2006)
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
DL Bhatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The identification of clinical candidate SB-480848:: A potent inhibitor of lipoprotein-associated phospholipase A2
JA Blackie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism
M Takahashi et al.
ATHEROSCLEROSIS (2002)
Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages
KLH Carpenter et al.
FEBS LETTERS (2001)
Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL
CC Hsieh et al.
ATHEROSCLEROSIS (2000)
Share Paper
